Linked e-resources
Details
Table of Contents
Preface; Contents; Chapter 1: Role of P-Glycoprotein for Resistance of Tumors to Anticancer Drugs: From Bench to Bedside; 1.1 Introduction; 1.2 Architecture and Function of the P-Glycoprotein; 1.3 Acquired Drug Resistance in Tumor Lines In Vivo; 1.4 Development of Resistance by Repeated Drug Treatments; 1.5 Reversal of Resistance After Cessation of Chemotherapy; 1.6 Inherent Drug Resistance in Human Lung Tumor Xenografts In Vivo; 1.7 P-Glycoprotein in Clinical Tumor Biopsies; 1.8 Prognostic Relevance of P-Glycoprotein for Treatment Outcome; 1.9 Conclusion and Perspectives; References
Chapter 2: Clinical Relevance of Multidrug-Resistance- Proteins (MRPs) for Anticancer Drug Resistance and Prognosis2.1 Introduction; 2.2 The ABCC/MRP Subfamily; 2.3 Specificity of MRPs for Chemotherapeutic Agents; 2.4 Association of MRPs With Cancer Survival; 2.4.1 MRP1; 2.4.2 MRP2; 2.4.3 MRP3; 2.4.4 MRP4; 2.4.5 MRP5; 2.4.6 MRP6; 2.4.7 MRP7; 2.4.8 MRP8; 2.5 Validation of Multidrug Resistance Proteins as Therapeutic Targets; 2.6 Can Knowledge of MRP Expression Improve Patient Outcome?; 2.6.1 MRP Expression as a Marker of Patient Prognosis
2.6.2 MRP Expression as a Method to Stratify Patients for Therapy2.7 MRPs as Targets for Therapy; 2.7.1 Small Molecule Modulators; 2.7.2 Monoclonal Antibodies; 2.7.3 RNA Interference; 2.8 Are There Roles for MRPs in Cancer Progression Other Than in Drug Resistance?; 2.9 Summary; References; Chapter 3: Role of Breast Cancer Resistance Protein (BCRP, ABCG2) in Cancer Outcomes and Drug Resistance; 3.1 Introduction; 3.2 Background Review: BCRP Functional Dynamics in Normal Tissues; 3.2.1 BCRP Structure and Function; 3.2.2 BCRP Expression; 3.2.3 BCRP Regulation
3.2.3.1 Pretranscriptional and Transcriptional Regulation3.2.3.2 Post-transcriptional Regulation; 3.2.3.3 BCRP Dimerization/Multimerization; 3.2.3.4 BCRP Degradation; 3.3 Impact of Non-neoplastic Expression of BCRP on Cancer Treatment Outcomes; 3.3.1 BCRP Polymorphisms; 3.3.2 BCRP Effects on Absorption, Distribution, Metabolism, and Elimination (ADME) of Antineoplastic Drugs; 3.3.3 BCRP Novel-Drug Delivery Mechanisms; 3.4 BCRP Expression in Human Cancers: Roles in Drug Resistance and Prognosis; 3.4.1 BCRP Expression and Hematologic Malignancies
3.4.1.1 Brief Summary of Findings and Controversies as of the Last Paper3.4.1.2 Regulation of ABCG2 in Hematologic Malignancies; 3.4.1.3 Interactions with Kinase Inhibitors; 3.4.1.4 BCRP Polymorphisms; 3.4.2 BCRP Expression and Solid Tumors (Summarized in Table 3.2); 3.4.2.1 Brief Summary of Findings, Controversies Since the Previous Paper; 3.4.2.2 Gastrointestinal Cancers; 3.4.2.3 Breast Cancer; 3.4.2.4 Lung Cancers; Small Cell Lung Cancer (SCLC); Non-small Cell Lung Cancer (NSCLC); 3.4.2.5 Head and Neck Cancers; 3.4.2.6 Ovarian Cancer; 3.4.2.7 Glioblastoma; 3.4.2.8 Prostate Cancer
Chapter 2: Clinical Relevance of Multidrug-Resistance- Proteins (MRPs) for Anticancer Drug Resistance and Prognosis2.1 Introduction; 2.2 The ABCC/MRP Subfamily; 2.3 Specificity of MRPs for Chemotherapeutic Agents; 2.4 Association of MRPs With Cancer Survival; 2.4.1 MRP1; 2.4.2 MRP2; 2.4.3 MRP3; 2.4.4 MRP4; 2.4.5 MRP5; 2.4.6 MRP6; 2.4.7 MRP7; 2.4.8 MRP8; 2.5 Validation of Multidrug Resistance Proteins as Therapeutic Targets; 2.6 Can Knowledge of MRP Expression Improve Patient Outcome?; 2.6.1 MRP Expression as a Marker of Patient Prognosis
2.6.2 MRP Expression as a Method to Stratify Patients for Therapy2.7 MRPs as Targets for Therapy; 2.7.1 Small Molecule Modulators; 2.7.2 Monoclonal Antibodies; 2.7.3 RNA Interference; 2.8 Are There Roles for MRPs in Cancer Progression Other Than in Drug Resistance?; 2.9 Summary; References; Chapter 3: Role of Breast Cancer Resistance Protein (BCRP, ABCG2) in Cancer Outcomes and Drug Resistance; 3.1 Introduction; 3.2 Background Review: BCRP Functional Dynamics in Normal Tissues; 3.2.1 BCRP Structure and Function; 3.2.2 BCRP Expression; 3.2.3 BCRP Regulation
3.2.3.1 Pretranscriptional and Transcriptional Regulation3.2.3.2 Post-transcriptional Regulation; 3.2.3.3 BCRP Dimerization/Multimerization; 3.2.3.4 BCRP Degradation; 3.3 Impact of Non-neoplastic Expression of BCRP on Cancer Treatment Outcomes; 3.3.1 BCRP Polymorphisms; 3.3.2 BCRP Effects on Absorption, Distribution, Metabolism, and Elimination (ADME) of Antineoplastic Drugs; 3.3.3 BCRP Novel-Drug Delivery Mechanisms; 3.4 BCRP Expression in Human Cancers: Roles in Drug Resistance and Prognosis; 3.4.1 BCRP Expression and Hematologic Malignancies
3.4.1.1 Brief Summary of Findings and Controversies as of the Last Paper3.4.1.2 Regulation of ABCG2 in Hematologic Malignancies; 3.4.1.3 Interactions with Kinase Inhibitors; 3.4.1.4 BCRP Polymorphisms; 3.4.2 BCRP Expression and Solid Tumors (Summarized in Table 3.2); 3.4.2.1 Brief Summary of Findings, Controversies Since the Previous Paper; 3.4.2.2 Gastrointestinal Cancers; 3.4.2.3 Breast Cancer; 3.4.2.4 Lung Cancers; Small Cell Lung Cancer (SCLC); Non-small Cell Lung Cancer (NSCLC); 3.4.2.5 Head and Neck Cancers; 3.4.2.6 Ovarian Cancer; 3.4.2.7 Glioblastoma; 3.4.2.8 Prostate Cancer